Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001

Author:

Vrooman Lynda M.12,Blonquist Traci M.3,Harris Marian H.4,Stevenson Kristen E.3,Place Andrew E.12,Hunt Sarah K.1,O’Brien Jane E.1,Asselin Barbara L.5,Athale Uma H.6,Clavell Luis A.7,Cole Peter D.8,Kelly Kara M.910,Laverdiere Caroline11,Leclerc Jean-Marie11,Michon Bruno12,Schorin Marshall A.13,Sulis Maria Luisa14,Welch Jennifer J. G.15,Neuberg Donna S.3,Sallan Stephen E.12,Silverman Lewis B.12

Affiliation:

1. Department of Pediatric Oncology, Dana-Farber Cancer Institute,

2. Division of Hematology/Oncology, Boston Children’s Hospital,

3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and

4. Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA;

5. Department of Pediatrics, Golisano Children’s Hospital, University of Rochester School of Medicine and Dentistry, Rochester, NY;

6. Division of Pediatric Hematology/Oncology, McMaster University, Hamilton, ON, Canada;

7. Division of Pediatric Oncology, San Jorge Children’s Hospital, San Juan, Puerto Rico;

8. Division of Pediatric Hematology/Oncology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY;

9. Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, NY;

10. Oishei Children's Hospital, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY;

11. Division of Hematology and Oncology, Hospital Sainte-Justine, University of Montreal, Montreal, QC, Canada;

12. Division of Hematology-Oncology, Centre Hospitalier Universitaire de Quebec–Université Laval, Quebec City, QC, Canada;

13. Inova Fairfax Hospital for Children, Falls Church, VA;

14. Division of Pediatric Oncology, Columbia University Medical Center, Morgan Stanley Children’s Hospital of New York–Presbyterian, New York, NY; and

15. Division of Pediatric Hematology-Oncology, Hasbro Children’s Hospital, Warren Alpert Medical School of Brown University, Providence, RI

Abstract

Key Points Childhood B-ALL patients, including those with VHR features, had favorable outcomes on DFCI 05-001 risk-stratified therapy. IKZF1 deletion was an independent predictor of inferior outcome, including among patients with low end-induction MRD.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3